Compare ABM & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ABM | NUVB |
|---|---|---|
| Founded | 1909 | 2018 |
| Country | United States | United States |
| Employees | N/A | 291 |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 1.6B |
| IPO Year | 1994 | N/A |
| Metric | ABM | NUVB |
|---|---|---|
| Price | $38.76 | $4.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $47.80 | $11.22 |
| AVG Volume (30 Days) | 453.0K | ★ 4.7M |
| Earning Date | 06-09-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.00% | N/A |
| EPS Growth | ★ 102.34 | N/A |
| EPS | ★ 0.64 | N/A |
| Revenue | ★ $8,745,900,000.00 | N/A |
| Revenue This Year | $5.71 | $182.76 |
| Revenue Next Year | $1.99 | $91.83 |
| P/E Ratio | $60.42 | ★ N/A |
| Revenue Growth | ★ 4.62 | N/A |
| 52 Week Low | $38.58 | $1.57 |
| 52 Week High | $52.94 | $9.75 |
| Indicator | ABM | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 26.44 | 34.56 |
| Support Level | N/A | $4.04 |
| Resistance Level | $46.93 | $5.73 |
| Average True Range (ATR) | 1.35 | 0.32 |
| MACD | -0.61 | -0.04 |
| Stochastic Oscillator | 10.72 | 16.38 |
ABM Industries Inc is a provider of integrated facility solutions. It offers its solutions through five segments: Business and Industry, Manufacturing and Distribution, Education, Aviation and Technical solutions. The company derives the majority of its revenue from the business and industry segment, which encompasses janitorial, facilities engineering, and parking services for commercial real estate properties and sports and entertainment venues, hospitals, as well as vehicle maintenance and other services to rental car providers. The company mainly operates in the United States of America.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.